Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Developing Antivirals and Repurposing Drugs for the Use against COVID-19
share announcement

Developing Antivirals and Repurposing Drugs for the Use against COVID-19

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccination Optimization".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 1266

Special Issue Editor

Dr. Chang Huang

E-Mail Website
Guest Editor
National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
Interests: SARS-CoV-2; PRRSV; antivirals; virus–host interaction

Special Issue Information

Dear Colleagues,

COVID19, caused by the novel coronavirus SARS-CoV-2, poses a great and ongoing threat to both the public health and the world economy. The implementation of mass vaccination against SARS-CoV-2 efficiently reduces the incidences of severe disease, morbidity, and mortality. However, vaccination is far from perfect due to widespread vaccine hesitancy and compromised vaccine efficacy against emerging SARS-CoV-2 variants. The spike protein, RNA-dependent RNA polymerase (RdRp), 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro) are crucial for the replication cycles and pathogenesis of SARS-CoV-2 and are deemed attractive drug targets. Therefore, another promising strategy would be developing new antivirals while working to repurpose drugs to treat COVID-19. The objective of this Special Issue of vaccines is to cover the most recent new antiviral development and repurposed drugs for the use against COVID-19. 

Dr. Chang Huang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • SARS-CoV-2
  • replication cycles
  • pathogenesis
  • antivirals
  • repurposed drugs

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

19 pages, 579 KiB  
Article
Inactivated Poliovirus Vaccine Booster Reduces the Likelihood of COVID-19 Outcomes in Individuals Primed with Oral Poliovirus Vaccination
by Brittany A. Comunale, Robin J. Larson, Yea-Jen Hsu, Erin Jackson-Ward, Chisom Azodoh, Aditi Singh and Lilly D. Engineer
Vaccines 2024, 12(3), 219; https://doi.org/10.3390/vaccines12030219 - 20 Feb 2024
Viewed by 1029
Abstract
Introduction: Prior research explores whether seasonal and childhood vaccines mitigate the risk of SARS-CoV-2 infection. Although there are trials investigating COVID-19 infection in response to the effects of the oral poliovirus vaccine (OPV), there has been no prior research assessing COVID-19 outcomes in [...] Read more.
Introduction: Prior research explores whether seasonal and childhood vaccines mitigate the risk of SARS-CoV-2 infection. Although there are trials investigating COVID-19 infection in response to the effects of the oral poliovirus vaccine (OPV), there has been no prior research assessing COVID-19 outcomes in recently immunized adults with the inactivated poliovirus vaccine (IPV). Methods: SARS-CoV-2 infection and COVID-19 symptoms were analyzed across a cohort of 282 adults who received an IPV booster. Bivariate and multivariate regression models explored associations among variables related to vaccination histories and COVID-19 outcomes. Results: One year post-IPV inoculation, participants who had never received OPV were more likely to test positive for SARS-CoV-2 and experience COVID-19 symptoms, compared to those who had previously received OPV (OR = 3.92, 95%CI 2.22–7.03, p < 0.001; OR = 4.45, 95%CI 2.48–8.17, p < 0.001, respectively). Those who had never received OPV experienced COVID-19 symptoms for 6.17 days longer than participants who had previously received OPV (95%CI 3.68–8.67, p < 0.001). Multivariate regression modeling indicated COVID-19 vaccination did not impact SARS-CoV-2 infection or COVID-19 symptoms in this sample of adults who had recently received IPV. Discussion: Findings suggest IPV may boost mucosal immunity among OPV-primed individuals, and COVID-19 vaccination may not provide additional protection among those who had received IPV. Future, larger-scale studies should measure the extent of protective effects against COVID-19 to inform public health policies in resource-deficient settings. Full article
(This article belongs to the Special Issue Developing Antivirals and Repurposing Drugs for the Use against COVID-19)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop